SBI Biotech

SBI Biotech is developing the novel therapeutic drugs in the pre-clinical stage for autoimmune diseases and cancers by targeting pDCs and B cells.

About Us
we strive for novel drug development targeting cancers and autoimmune diseases.

Read More
Product Pipeline
We focus on development of immune modulation drugs with lower side effects and higher efficacies.
Read More
Technology
We are concentrating on development of antibody drugs targeting pDCs and DNA nucleotide drugs targeting TLRs.
Read More
Our Business
We have multiple licensing plans readied from early preclinical stage to clinical stage depending on the nature of each pipeline.
Read More

Recent News

10/15/2019: The address of our laboratory (Ginkgo Biomedical Research Institute) has changed due to the implementation of the housing number display system.
07/17/2018: Announcement of new director.[Written in Japanese]
08/28/2017: Our headquarter office is moved to Izumi Garden Tower 15F.
10/21/2016: SBI Biotech’s Licensed product, an Anti-ILT7 antibody (MEDI7734) has achieved a Developmental Milestone in a Phase I Clinical Trial[Written in Japanese]
04/19/2016: SBI Biotech’s Licensed product, an Anti-ILT7 antibody, has IND approval to initiate a Phase Ⅰ Clinical Trial(PDF/39KB)
03/15/2016: SBI Biotech’s Subsidiary Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase Ⅲ Studies and One Phase Ⅱ Study of RNAi-Based Therapeutics for Kidney and Eye Indications[Written in Japanese](PDF/154KB)